Specificity and sensitivity of biotinidase activity measured from dried blood spot by colorimetric method

2019 ◽  
Vol 26 (10) ◽  
pp. 2306
Author(s):  
Halil Kazanasmaz ◽  
Nurgul Atas ◽  
Meryem Karaca
Keyword(s):  
Colorimetric Method ◽  
Dried Blood Spot ◽  
Specificity And Sensitivity ◽  
Biotinidase Activity ◽  
Blood Spot

Quantitative Analytical Method for the Determination of Biotinidase Activity in Dried Blood Spot Samples

2015 ◽  
Vol 87 (20) ◽  
pp. 10573-10578 ◽  
Author(s):  
Eszter Szabó ◽  
Ildikó Szatmári ◽  
László Szőnyi ◽  
Zoltán Takáts
Keyword(s):  
Analytical Method ◽  
Dried Blood Spot ◽  
Biotinidase Activity ◽  
Blood Spot

scholarly journals A simple method for quantification of biotinidase activity in dried blood spot and its application to screening of biotinidase deficiency.

1987 ◽  
Vol 152 (4) ◽  
pp. 339-346 ◽  
Author(s):  
AKIHIRO YAMAGUCHI ◽  
MASARU FUKUSHI ◽  
OSAMU ARAI ◽  
YOSHIKIYO MIZUSHIMA ◽  
YASUMASA SATO ◽  
...  
Keyword(s):  
Biotinidase Deficiency ◽  
Dried Blood Spot ◽  
Simple Method ◽  
Biotinidase Activity ◽  
Blood Spot

scholarly journals Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders

2020 ◽  
Vol 6 (2) ◽  
pp. 26 ◽  
Author(s):  
Stuart J. Moat ◽  
Roanna S. George ◽  
Rachel S. Carling
Keyword(s):  
Metabolic Disorders ◽  
Ultra Performance Liquid Chromatography ◽  
Dried Blood Spot ◽  
Specificity And Sensitivity ◽  
Low Concentrations ◽  
Inherited Metabolic Disorders ◽  
The 1960S ◽  
Analytical Technology ◽  
Test Result ◽  
Blood Spot

Monitoring of patients with inherited metabolic disorders (IMDs) using dried blood spot (DBS) specimens has been routinely used since the inception of newborn screening (NBS) for phenylketonuria in the 1960s. The introduction of flow injection analysis tandem mass spectrometry (FIA–MS/MS) in the 1990s facilitated the expansion of NBS for IMDs. This has led to increased identification of patients who require biochemical monitoring. Monitoring of IMD patients using DBS specimens is widely favoured due to the convenience of collecting blood from a finger prick onto filter paper devices in the patient’s home, which can then be mailed directly to the laboratory. Ideally, analytical methodologies with a short analysis time and high sample throughput are required to enable results to be communicated to patients in a timely manner, allowing prompt therapy adjustment. The development of ultra-performance liquid chromatography (UPLC–MS/MS), means that metabolic laboratories now have the capability to routinely analyse DBS specimens with superior specificity and sensitivity. This advancement in analytical technology has led to the development of numerous assays to detect analytes at low concentrations (pmol/L) in DBS specimens that can be used to monitor IMD patients. In this review, we discuss the pre-analytical, analytical and post-analytical variables that may affect the final test result obtained using DBS specimens used for monitoring of patients with an IMD.

scholarly journals Validation of high-throughput, semiquantitative solid phase SARS coronavirus-2 serology assays in serum and dried blood spot matrices

Bioanalysis ◽  
2021 ◽  
Author(s):  
Leo Maritz ◽  
Nicholas J Woudberg ◽  
Amber C Bennett ◽  
Andreia Soares ◽  
Florian Lapierre ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Solid Phase ◽  
Dried Blood Spot ◽  
Sars Coronavirus ◽  
Diagnostic Specificity ◽  
Global Pandemic ◽  
Specificity And Sensitivity ◽  
Infection Monitoring ◽  
Blood Spot

Aim: Serological assays for the detection of anti-SARS coronavirus-2 (SARS-CoV-2) antibodies are essential to the response to the global pandemic. A ligand binding-based serological assay was validated for the semiquantitative detection of IgG, IgM, IgA and neutralizing antibodies (nAb) against SARS-CoV-2 in serum. Results: The assay demonstrated high levels of diagnostic specificity and sensitivity (85–99% for all analytes). Serum IgG, IgM, IgA and nAb correlated positively (R2 = 0.937, R2 = 0.839, R2 = 0.939 and R2 = 0.501, p < 0.001, respectively) with those measured in dried blood spot samples collected using the hemaPEN® microsampling device (Trajan Scientific and Medical, Victoria, Australia). In vitro SARS-CoV-2 pseudotype neutralization correlated positively with the solid phase nAb signals in convalescent donors (R2 = 0.458, p < 0.05). Conclusion: The assay is applicable in efficacy studies, infection monitoring and postmarketing surveillance following vaccine rollout.

scholarly journals Fabry Cardiomyopathy: Current Practice and Future Directions

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1532
Author(s):  
Jeffrey Yim ◽  
Olivia Yau ◽  
Darwin F. Yeung ◽  
Teresa S. M. Tsang
Keyword(s):  
Fabry Disease ◽  
Early Stage ◽  
Point Of Care ◽  
Left Ventricular ◽  
The Body ◽  
Cardiac Biomarkers ◽  
Dried Blood Spot ◽  
Point Of Care Ultrasound ◽  
Enzyme Replacement ◽  
Blood Spot

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the galactosidase A (GLA) gene that result in deficient galactosidase A enzyme and subsequent accumulation of glycosphingolipids throughout the body. The result is a multi-system disorder characterized by cutaneous, corneal, cardiac, renal, and neurological manifestations. Increased left ventricular wall thickness represents the predominant cardiac manifestation of FD. As the disease progresses, patients may develop arrhythmias, advanced conduction abnormalities, and heart failure. Cardiac biomarkers, point-of-care dried blood spot testing, and advanced imaging modalities including echocardiography with strain imaging and magnetic resonance imaging (MRI) with T1 mapping now allow us to detect Fabry cardiomyopathy much more effectively than in the past. While enzyme replacement therapy (ERT) has been the mainstay of treatment, several promising therapies are now in development, making early diagnosis of FD even more crucial. Ongoing initiatives involving artificial intelligence (AI)-empowered interpretation of echocardiographic images, point-of-care dried blood spot testing in the echocardiography laboratory, and widespread dissemination of point-of-care ultrasound devices to community practices to promote screening may lead to more timely diagnosis of FD. Fabry disease should no longer be considered a rare, untreatable disease, but one that can be effectively identified and treated at an early stage before the development of irreversible end-organ damage.

scholarly journals Use of dried blood spot samples for SARS-CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay

2021 ◽  
Vol 136 ◽  
pp. 104739
Author(s):  
Ranya Mulchandani ◽  
Ben Brown ◽  
Tim Brooks ◽  
Amanda Semper ◽  
Nicholas Machin ◽  
...  
Keyword(s):  
High Throughput ◽  
Dried Blood Spot ◽  
Antibody Detection ◽  
Blood Spot

scholarly journals A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Amelia E. Sancilio ◽  
Richard T. D’Aquila ◽  
Elizabeth M. McNally ◽  
Matthew P. Velez ◽  
Michael G. Ison ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Venous Blood ◽  
Host Cells ◽  
Dried Blood Spot ◽  
Blood Collection ◽  
Widespread Application ◽  
Live Virus ◽  
Dilution Series ◽  
Wide Range ◽  
Blood Spot

AbstractThe spike protein of SARS-CoV-2 engages the human angiotensin-converting enzyme 2 (ACE2) receptor to enter host cells, and neutralizing antibodies are effective at blocking this interaction to prevent infection. Widespread application of this important marker of protective immunity is limited by logistical and technical challenges associated with live virus methods and venous blood collection. To address this gap, we validated an immunoassay-based method for quantifying neutralization of the spike-ACE2 interaction in a single drop of capillary whole blood, collected on filter paper as a dried blood spot (DBS) sample. Samples are eluted overnight and incubated in the presence of spike antigen and ACE2 in a 96-well solid phase plate. Competitive immunoassay with electrochemiluminescent label is used to quantify neutralizing activity. The following measures of assay performance were evaluated: dilution series of confirmed positive and negative samples, agreement with results from matched DBS-serum samples, analysis of results from DBS samples with known COVID-19 status, and precision (intra-assay percent coefficient of variation; %CV) and reliability (inter-assay; %CV). Dilution series produced the expected pattern of dose–response. Agreement between results from serum and DBS samples was high, with concordance correlation = 0.991. Analysis of three control samples across the measurement range indicated acceptable levels of precision and reliability. Median % surrogate neutralization was 46.9 for PCR confirmed convalescent COVID-19 samples and 0.1 for negative samples. Large-scale testing is important for quantifying neutralizing antibodies that can provide protection against COVID-19 in order to estimate the level of immunity in the general population. DBS provides a minimally-invasive, low cost alternative to venous blood collection, and this scalable immunoassay-based method for quantifying inhibition of the spike-ACE2 interaction can be used as a surrogate for virus-based assays to expand testing across a wide range of settings and populations.

Sign in / Sign up

Export Citation Format

Share Document